Skip to main content
NCBI home page
Journal of Cancer Research and Clinical Oncology logoLink to Journal of Cancer Research and Clinical Oncology
. 1993 Jul;119(9):527–532. doi: 10.1007/BF01686462

Pharmacological and molecular characterization of intrinsic and acquired doxorubicin resistance in murine tumor cell lines

Brigitte Schott 1,2, Danielle Londos-Gagliardi 1,2, Colette Ries 1,2, Sylvie Huet 1,2, Jacques Robert 1,2,✉
PMCID: PMC12200566  PMID: 8100823

Abstract

We have studied the pharmacological parameters of doxorubicin resistance in three lines of murine cells selected by long-term culture in the presence of this drug or vincristine. A line originating from rat hepatoma spontaneously presented an intrinsic doxorubicin resistance as compared to the other lines, originating from a rat glioblastoma and from simian-virus-40-transformed mouse hepatocytes. This intrinsic resistance, as well as the doxorubicin resistance exhibited by the vincristine-selected glioblastoma variant, could be entirely attributed to decreased drug accumulation due to drug efflux. In contrast, the doxorubicin-selected variants of the three lines exhibited an intracellular tolerance to this drug. Despite a reduction in drug accumulation when exposed to the same amount of doxorubicin, they accumulated 6–12 times more doxorubicin than wild lines when submitted to equitoxic exposures. Verapamil could restore, in these lines the doxorubicin accumulation observed in sensitive lines but could not restore doxorubicin cytotoxicity. Quantitative evaluation of P-glycoprotein expression by Western blotting with the C219 antibody indicated that the wild hepatoma line overexpressed P-glycoprotein by a factor of 5 in comparison with the other wild lines, and that the vincristine-selected glioblastoma variant overexpressed this protein almost as much as the doxorubicin-selected variants. These observations favor the existence of P-glycoprotein-independent mechanisms of doxorubicin resistance, which are added to the classical multidrug-resistant phenotype in doxorubicin-selected highly resistant variant cell lines.

Key words: Multidrug resistance, Anthracyclines, P-glycoprotein, Drug resistance reversal

References

  1. Akman SA, Forrest G, Chu FF, Esworthy RS, Doroshow JA (1990) Antioxidant and xenobiotic-metabolizing enzyme gene expression in doxorubicin-resistant MCF-7 breast cancer cells. Cancer Res 50:1397–1402 [PubMed] [Google Scholar]
  2. Batist G, Tulpule A, Sinha BK, Katki AG, Myers CE Cowan KH (1986) Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem 261:15544–15549 [PubMed] [Google Scholar]
  3. Beck WT, Cirtain MC, Danks MK, Felsted RL, Safa AR, Wolverton JS, Suttle DP Trent JM (1987) Pharmacological, molecular, and cytogenetic analysis of “atypical” multidrug-resistance human leukemic cells. Cancer Res 47:5455–5460 [PubMed] [Google Scholar]
  4. Benda P, Lightbody J, Sato G, Levine L, Sweet W (1968) Differentiation rat glial cell strain in tissue culture. Science 161:370–371 [DOI] [PubMed] [Google Scholar]
  5. Bonnet F, Coindre JM, Robert J (1990) Expression du gène de la multidrug-resistance dans les cancers du sein. Bull Cancer 77:131s-134s [Google Scholar]
  6. Bradley G, Juranka PF, Ling V (1988) Mechanism of multidrug resistance. Biochim Biophys Acta 948:87–128 [DOI] [PubMed] [Google Scholar]
  7. Capranico G, Dasdia T, Zunino F (1986) Comparison of doxorubicin induced DNA damage in doxorubicin-sensitive and-resistant P388 murine leukemia cells. Int J Cancer 37:227–231 [DOI] [PubMed] [Google Scholar]
  8. Chan HSL, Thorner PS, Hadjad G, Ling V (1990) Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 8:689–704 [DOI] [PubMed] [Google Scholar]
  9. Chang BK, Brenner DE, Gutman R (1989) Dissociation of the verapamil-induced enhancement of doxorubicin cytotoxicity from changes in cellular accumulation or retention of doxorubicin in pancreatic cancer cell lines. Anticancer Res 9:347–352 [PubMed] [Google Scholar]
  10. Cole SPC, Chanda ER, Dicke FP, Gerlach JH, Mirski SEL (1991) Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line. Evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase-II. Cancer Res 51:3345–3352 [PubMed] [Google Scholar]
  11. Croop JM, Raymond M, Haber D, Devault A, Arceci RJ, Gros, P, Housman DE (1989) The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol 9:1346–1350 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Endicott JA, Ling V (1989) The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58:137–171 [DOI] [PubMed] [Google Scholar]
  13. Fairchild CR, Moscow JA, O'Brien EE, Cowan KH (1990) Multidrug resistance in cells transfected with human genes encoding a variant P-glycoprotein and gluthatione-S-tranferase.-ϑ. Mol Pharmacol 37:801–809 [PubMed] [Google Scholar]
  14. Fry AM, Chresta CM, Davies SM, Walker MC, Harris AL, Hartley JA, Masters JRW, Hickson ID (1991) Relationship between topoisomerase-II level and chemosensitivity in human tumor cell lines. Cancer Res 51:6592–6595 [PubMed] [Google Scholar]
  15. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Pirker R, Green A, Crost W, Brodeur GM, Lieber M, Cossman J, Gottesman MM, Pastan I (1989) Expression of a multidrug resistance gene in human cancers. JNCI 81:116–124 [DOI] [PubMed] [Google Scholar]
  16. Greenberger LM, Williams SS, Horwitz SB (1987) Biosynthesis of heterogeneous forms of multidrug resistance-associated glycoproteins. J Biol Chem 262:13685–13689 [PubMed] [Google Scholar]
  17. Gros P, Neriah B, Croop JM, Housman DE (1986) Isolation and expression of a cDNA (mdr) that confers multidrug-resistance. Nature 323:728–731 [DOI] [PubMed] [Google Scholar]
  18. Hsu SIH, Lothstein L, Horwitz SB (1989) Differential overexpression of three mdr gene family members in multidrug-resistant J774.2 mouse cells. J Biol Chem 264:12053–12062 [PubMed] [Google Scholar]
  19. Kessel D, Wilberding C (1985) Anthracycline resistance in P388 murine leukemia and its circumvention by calcium antagonists. Cancer Res. 45:1687–1691 [PubMed] [Google Scholar]
  20. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685 [DOI] [PubMed] [Google Scholar]
  21. Larsen A, Jacquemin-Sablon A (1989) Multiple resistance mechanisms in Chinese hamster cells resistant to 9-hydroxyellipticine. Cancer Res 49:7115–7119 [PubMed] [Google Scholar]
  22. Londos-Gagliardi D, Vrignaud P, Robert J (1984) On the resistance of cultured cells to doxorubicin. Stud Biophys 104:155–160 [Google Scholar]
  23. Merkel DE, Fuqua SAW, Tandon AK, Hill SM, Buzdar AU, McGuire WL (1989) Electrophoretic analysis of 248 clinical breast cancer specimens for P-glycoprotein overexpression or gene amplification. J Clin Oncol 7:1129–1136 [DOI] [PubMed] [Google Scholar]
  24. Morrow CS, Cowan KH (1990) Multidrug resistance associated with altered topoisomerase II activity. Topoisomerases II as targets for rational drug design. JNCI 82:638–639 [DOI] [PubMed] [Google Scholar]
  25. Pastan I, Gottesman M (1987) Multiple-drug resistance in human cancer. N Engl J Med 316:1388–1393 [DOI] [PubMed] [Google Scholar]
  26. Safa AR (1988) Photoaffinity labeling of the multidrug-resistance-related P-glycoprotein with photoactive analogs of verapamil. Proc Natl Acad Sci USA 85:7187–7191 [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Samuels BR, Murray JL, Cohen MB, Safa AR, Sinha BK, Townsend AJ, Beckett MA, Weichselbaum RR (1991) Increased glutathione peroxidase activity in a human sarcoma cell line with inherent doxorubicin resistance. Cancer Res 51:521–527 [PubMed] [Google Scholar]
  28. Schott B, Robert J (1989) Comparative cytotoxicity, DNA synthesis inhibition and drug incorporation of eight anthracyclines in a model of doxorubicin-sensitive and-resistant rat glioblastoma cells. Biochem Pharmacol 38:167–172 [DOI] [PubMed] [Google Scholar]
  29. Schuurhuis GJ, Broxterman HJ, Cervantes A, van Heijningen THM, de Lange JHM, Baak JPA, Pinedo HM, Lankelma J (1989) Quantitative determination of factors contributing to doxorubicin resistance in multidrug-resistante cells. JNCI 81:1887–1892 [DOI] [PubMed] [Google Scholar]
  30. Singh SV, Nair S, Ahmad H, Awasthi YC, Krishan A (1989) Glutathione-S-transferase and glutathione peroxidases in doxorubicin-resistant murine leukemic P388 cells. Biochem Pharmacol 38:3505–3510 [DOI] [PubMed] [Google Scholar]
  31. Thompson EB, Tomkin GM, Curran JF (1966) Induction of tyrosin α-ketoglutarate transaminase by steroid hormones in a newly established tissue culture cell line. Proc Natl Acad Sci USA 56:296–304 [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Ueda K, Cardarelli C, Gottesman MM, Pastan I (1987) Expression of a full-length cDNA for the human MDR1 gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 84:3004–3008 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Cancer Research and Clinical Oncology are provided here courtesy of Springer

RESOURCES